此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

使用FARAPULSE™ PFA系统输送新型波形的评估 (IMPULSE-EVO)

2026年10月21日 更新者:Boston Scientific Corporation

使用FARAPULSE™ PFA系统向房颤患者输送新型波形的一项多中心评估

This is a multicenter, prospective, single-arm, feasibility study to evaluate the safety and effectiveness of the waveforms being delivered using the FARAPULSE PFA System in patients with Paroxysmal Atrial Fibrillation (PAF) and Persistent Atrial Fibrillation (PersAF).

研究概览

详细说明

The objective of this feasibility study is to:

  • Evaluate the initial safety and acute performance of investigational waveform(s) delivered using the FARAPULSE™ PFA System in patients with Paroxysmal Atrial Fibrillation (PAF) and Persistent Atrial Fibrillation (PersAF).
  • Assess the feasibility of the ablation workflow and waveform delivery.
  • Characterize acute and chronic lesion durability, procedure efficiency, and waveform exposure patterns.

研究类型

介入性

注册 (估计的)

200

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

      • Split、克罗地亚、21 000
        • 招聘中
        • Klinicki Bolnicki Centar Split
        • 首席研究员:
          • Ante Anic
        • 接触:
      • Taipei、台湾、1127
        • 尚未招聘
        • Taipei Veterans General Hospital-Hospital
        • 首席研究员:
          • Li-Wei Lo
      • Prague、捷克语、15030
        • 招聘中
        • Na Homolce Hospital
        • 首席研究员:
          • Petr Neuzil
        • 接触:
      • Hong Kong、香港
        • 招聘中
        • Queen Mary Hospital
        • 接触:
        • 首席研究员:
          • Hung Fat Tse

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  1. ≥ 18 years of age, or older if required by local law

  2. Persistent Atrial Fibrillation or Paroxysmal Atrial Fibrillation

    1. Persistent AF Documented:

      • Physician's note confirming the presence of persistent atrial fibrillation and the arrhythmia symptoms
      • Within 180 days prior to Enrollment: A 24-hour continuous ECG recording confirming continuous AF OR Two (2) ECGs from any regulatory-cleared rhythm monitoring device showing continuous AF taken at least 7 days apart.

      OR

    2. Paroxysmal AF Documented:

      • Physician's note confirming the presence of paroxysmal atrial fibrillation and the arrhythmia symptoms
      • Within 180 days of the Enrollment Date, one (1) ECG from any regulatory-cleared rhythm monitoring device showing atrial Fibrillation (AF)
  3. Willing and capable of providing informed consent

  4. Willing and capable of participating in all follow-up assessments and testing associated with this clinical investigation at an approved clinical investigational center

Exclusion Criteria:

  1. Atrial exclusions - any of the following atrial conditions:

    1. Left atrial anteroposterior diameter ≥ 5.5 cm, or if LA diameter is not available, LA non-indexed volume > 100 mL. If both values are available, only the LA diameter will be used to confirm eligibility.
    2. Any prior atrial endocardial, epicardial, or surgical ablation procedure for arrhythmia other than ablation for right-sided SVT or cavotricuspid isthmus ablation
    3. Any prior atrial surgery
    4. Current atrial myxoma
    5. Current Left Atrial Thrombus
    6. Any PV abnormality, stenosis, or stenting (common and middle PVs are admissible)
  2. Cardiovascular Conditions - Any of the following cardiovascular conditions:

    1. History of sustained ventricular tachycardia (VT) or any ventricular fibrillation (VF)

    2. Atrial fibrillation that is secondary to electrolyte imbalance, thyroid disease, alcohol, or other reversible/non-cardiac causes

    3. Cardiac Devices and Implants:

      • Current or anticipated pacemaker, implantable cardioverter-defibrillator or cardiac resynchronization therapy devices.
      • Interatrial baffle, patent foramen ovale, or atrial septal defect closure device or patch.
      • Any Left Atrial Appendage Closure or Occlusion Device, except a WATCHMAN™ device implanted > 90 days before Enrollment
    4. Valvular Disease - Presence of any of the following:

      • Any prosthetic heart valve, ring or repair
      • Moderate to severe mitral valve stenosis
      • More than moderate mitral regurgitation (≥ 3+)
      • Moderate to severe aortic stenosis
    5. Cardiomyopathy - Hypertrophic cardiomyopathy

    6. Access Issues - Any IVC filter, known inability to obtain vascular access, or other contraindication to femoral access

    7. Anticipated Cardiac Surgery - Awaiting cardiac transplantation or other planned cardiac surgery within the next 12 months

  3. Congenital Conditions - Any of the following congenital conditions:

    a. Congenital heart disease with any clinically significant residual anatomic or conduction abnormality

  4. Baseline Conditions - Any of the following conditions at Baseline:

    1. Heart failure - Heart failure associated with NYHA Class III or IV
    2. Ejection Fraction - Most recent documented LVEF < 40% within the previous 12 months
    3. Obesity: Body Mass Index (BMI) > 45.0 kg/m^2
    4. Hematologic Condition: Known coagulopathy or bleeding disorder
    5. Anticoagulation Contraindication: Contraindication to, or unwillingness to use, systemic anticoagulation, or acceptable alternatives, pre-, intra- and post-procedure to achieve adequate anticoagulation
    6. Pregnancy - Women who are confirmed to be pregnant or lactating at the time of the ablation procedure
    7. Pulmonary Disease - Severe lung disease, severe pulmonary hypertension, or any lung disease involving abnormal blood gases or requiring supplemental oxygen
    8. Malignancy - Active malignancy (other than non-melanoma skin cancers)
    9. Gastrointestinal - Clinically significant gastrointestinal problems involving the esophagus or stomach, including severe or erosive esophagitis, uncontrolled gastric reflux, gastroparesis, esophageal candidiasis or active gastroduodenal ulceration
    10. Infection - Known active systemic infection
    11. Sleep Apnea - Untreated diagnosed obstructive sleep apnea with apnea-hypopnea index classification of severe (> 30 events per hour) as per the guidelines
    12. Life Expectancy - Predicted life expectancy of less than one (1) year per investigator medical judgment
    13. Concurrent Enrollment - Subjects who are currently enrolled in another investigational study or registry that would directly interfere with the current study, except when the subject is participating in a mandatory governmental registry, or a purely observational registry with no associated treatments; each instance must be brought to the attention of the sponsor to determine eligibility
  5. Any of the following events within 90 days of the Consent Date:

    1. Coronary disease - Myocardial infarction (MI), unstable angina or coronary intervention
    2. Pericardium - Pericarditis or symptomatic pericardial effusion
    3. GI Bleeding - Gastrointestinal bleeding
    4. Cardiac Surgery - Any cardiac surgery
    5. Neurovascular Event - Stroke, TIA, or intracranial bleeding
    6. Thromboembolism - Any active non-neurologic thrombus and/or thromboembolic event
    7. Carotid Intervention - Carotid stenting or endarterectomy
    8. Diabetes - Uncontrolled diabetes mellitus or a recorded HgbA1c > 8.0%
  6. Medical History - Any of the following conditions in the Medical History

    1. Transplantation - Solid organ or hematologic transplant, or currently being evaluated for a transplant
    2. Diaphragmatic Abnormality - Any prior history or current evidence of hemi-diaphragmatic paralysis or paresis
    3. Coronary Disease - Any documented history of Prinzmetal angina or severe non-revascularizable coronary disease
    4. Renal Disease - Renal insufficiency if an estimated glomerular filtration rate (eGFR) is < 30 mL/min/1.73 m2, or with any history of renal dialysis or renal transplant
    5. General Medical Conditions - Any other general health conditions that, in the investigator's medical opinion, would prevent participation in the study, interfere with assessment or therapy, significantly raise the risk of study participation, or modify outcome data or its interpretation.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
其他:FARAPULSE™ Pulsed Field Ablation (PFA) System

Single Arm Prospective

The FARAWAVE™ PFA Catheter will be used to deliver the investigational waveform(s) for the isolation of pulmonary veins and posterior wall in the treatment of paroxysmal and persistent atrial fibrillation.

The FARASTAR™ Generator will be used in conjunction with the FARAWAVE™ PFA Catheter to deliver the investigational waveform(s) for the isolation of pulmonary veins and posterior wall in the treatment of paroxysmal and persistent atrial fibrillation.

The FARADRIVE™ Steerable Sheath will be used for percutaneous catheter introduction into the chambers of the heart, including the left side of the heart through the interatrial septum.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Device or procedure-related Composite Adverse Events (CAEs)
大体时间:Ablation Procedure Day 0 - Day 7; Day 0 - Day 30; Day 0 - Day 60

The incidence of device or procedure-related Composite Adverse Events (CAEs) following the Index Procedure will be evaluated.

Ablation Procedure Day 0 - Day 7; Day 0 - Day 30; Day 0 - Day 60
Acute Procedural Success
大体时间:During the Ablation Procedure

The proportion of subjects with percutaneous endocardial creation of a complete, electrically isolating set of lesions around the ostia of the pulmonary veins (PV) and posterior wall (PW) during the Index Procedure, as clinically assessed by entrance and/or exit block or confirmed by electroanatomic mapping.

During the Ablation Procedure

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年2月12日

初级完成 (估计的)

2028年2月1日

研究完成 (估计的)

2028年2月1日

研究注册日期

首次提交

2026年2月11日

首先提交符合 QC 标准的

2026年2月26日

首次发布 (实际的)

2026年3月2日

研究记录更新

最后更新发布 (实际的)

2026年10月23日

上次提交的符合 QC 标准的更新

2026年10月21日

最后验证

2026年10月1日

更多信息

与本研究相关的术语

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

在美国制造并从美国出口的产品

是的

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅